| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 21-08-03 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +0.64% | +1.32% | +7.01% | +83.24% | 44.96B | |
| -0.20% | -3.59% | +38.01% | +87.26% | 33.53B | |
| +0.43% | -0.82% | -7.52% | +44.78% | 11.67B | |
| -0.17% | +1.40% | +12.81% | +116.51% | 11.62B | |
| -0.68% | +0.78% | +37.07% | +126.43% | 8.97B | |
| +1.80% | -0.25% | +17.37% | +42.74% | 6.89B | |
| -1.12% | -0.56% | +40.12% | -18.60% | 6.55B | |
| +1.38% | +0.38% | +32.62% | +240.54% | 6.32B | |
| -0.45% | -2.96% | -39.97% | -6.82% | 5.12B | |
| Average | +0.90% | -0.88% | +15.28% | +79.56% | 15.07B | |
| Weighted average by Cap. | +0.24% | -1.10% | +17.45% | +83.58% |
Employees
2,191
Sector
Pharmaceuticals
